v3.26.3
License and Collaboration Agreements - Additional Information (Detail)
 1 Months Ended 3 Months Ended 9 Months Ended
Jun. 30, 2026
USD ($)
Aug. 31, 2025
USD ($)
Mar. 31, 2025
USD ($)
Nov. 30, 2021
USD ($)
Sep. 30, 2026
USD ($)
ProductCandidate
Sep. 30, 2025
USD ($)
Sep. 30, 2026
USD ($)
ProductCandidate
Country
Sep. 30, 2025
USD ($)
Dec. 31, 2025
USD ($)
Jun. 30, 2025
USD ($)
Dec. 31, 2024
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Milestone payment upon commencement of clinical trials in humans             $ 444,000,000        
Milestone payment upon submission of regulatory approval filings             86,500,000        
Milestone payment upon achievement of specified sales targets for licensed products             1,530,000,000        
Deferred revenue, current and non-current $ 25,286,000       $ 22,206,000 $ 34,381,000 22,206,000 $ 34,381,000 $ 29,395,000 $ 37,781,000 $ 115,000
Aggregate transaction price of license agreements             $ 23,300,000        
Aggregate transaction price of license agreements, expected satisfaction period             4 years        
Revenue recognized upon achievement of development milestones         0 0 $ 100,000,000 0      
Accounts receivable 107,189,000       8,986,000 28,112,000 8,986,000 28,112,000 28,691,000 $ 21,783,000 $ 20,947,000
Accounts receivable, Current         8,536,000   8,536,000   26,379,000    
Accounts receivable, Non current         450,000   450,000   2,312,000    
Abb Vie Collaboration And License Agreement                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Revenue recognized upon achievement of development milestones             100,000,000        
Up-front fee paid       $ 370,000,000              
Milestone fee payments upon achievement of various development and commercialization       1,380,000,000              
Transaction price of license       470,000,000 470,000,000   470,000,000        
Transaction price of licence increase in amount upon achievement of First DR Milestone 100,000,000           100,000,000        
Up-front payment received       370,000,000              
Change in transaction price         0 0   0      
Revenue recognized         0 0   0      
Milestone due   $ 200,000,000                  
Milestone payment due upon achievement of First DR Milestone 100,000,000                    
Milestone payment upon first patient dosed in the Phase IIb/III trial   100,000,000                  
Milestone payment earned upon achievement of First DR Milestone $ 100,000,000                    
Milestone payment upon first patient dosed in the subsequent Phase III trial   $ 100,000,000                  
Abb Vie Collaboration And License Agreement | Location, Statement of Financial Position, Balance [Axis]: us-gaap:OtherAssetsCurrent                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Due from related parties, current         7,500,000   7,500,000   10,900,000    
Nippon Shinyaku Collaboration and License Agreement [Member]                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Accounts receivable         2,500,000   2,500,000   4,100,000    
Deferred revenue         22,200,000   22,200,000   29,400,000    
Deferred revenue, Current         6,000,000   6,000,000   10,500,000    
Deferred revenue, Noncurrent         16,200,000   16,200,000   18,900,000    
Up-front fee paid     $ 110,000,000                
Transaction price of license         110,000,000   110,000,000        
Estimated variable consideration         5,600,000   5,600,000        
Change in transaction price         0 $ 0 0 $ 0      
Novartis License Agreement [Member] | Novartis [ Member ]                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Accounts receivable         5,500,000   5,500,000   $ 24,100,000    
Sales Based Milestones | Abb Vie Collaboration And License Agreement                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Milestone fee payments upon achievement of various development and commercialization       820,000,000              
Transaction price of license         820,000,000   820,000,000        
Sales Based Milestones | Nippon Shinyaku Collaboration and License Agreement [Member]                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Milestone fee received upon achievement of specified development and sales based milestones     660,000,000                
Transaction price of license         660,000,000   660,000,000        
Development Milestone | Abb Vie Collaboration And License Agreement                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Milestone fee payments upon achievement of various development and commercialization       $ 562,500,000              
Transaction price of license         462,500,000   462,500,000        
Development Milestone | Nippon Shinyaku Collaboration and License Agreement [Member]                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Milestone fee received upon achievement of specified development and sales based milestones     40,000,000                
Transaction price of license         $ 40,000,000   40,000,000        
Maximum [Member]                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Aggregate milestone payment for all the targets             $ 2,060,000,000.00        
Maximum [Member] | Nippon Shinyaku Collaboration and License Agreement [Member]                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Milestone fee received upon achievement of specified development and sales based milestones     $ 700,000,000                
N A V Technology Platform [Member]                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Number of commercial product candidates | ProductCandidate         2   2        
HCR [Member] | Novartis License Agreement [Member] | Novartis [ Member ]                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Accounts receivable, current         $ 4,200,000   $ 4,200,000        
Zolgensma Royalties [Member]                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Number of countries where licensed patents remain active | Country             20